Supplementary Date (For Publication) from Targeting Hypoxic Prostate Tumors Using the Novel Hypoxia-Activated Prodrug OCT1002 Inhibits Expression of Genes Associated with Malignant Progression

Authors:
  • HNHeather Nesbitt
    Heather Nesbitt
  • NBNiall M. Byrne
    Niall M. Byrne
  • SWS. Nicole Williams
    S. Nicole Williams
  • LMLouise Ming
    Louise Ming
  • JWJenny Worthington
    Jenny Worthington
  • RERachel J. Errington
    Rachel J. Errington
  • LPLaurence H. Patterson
    Laurence H. Patterson
  • PSPaul J. Smith
    Paul J. Smith
  • SMStephanie R. McKeown
    Stephanie R. McKeown
  • DMDeclan J. McKenna
    Declan J. McKenna

Abstract
Supplementary Data contains Supplementary Table S1: Primer Sequences Supplementary Figure S1: Gene Layout on RealTime Ready custom 96 well panel Supplementary Figure S2: OCT1002 targets 22Rv1 and PC3 in hypoxic conditions Supplementary Figure S3: OCT1002 induces apoptosis in LNCAP-luc spheroids Supplementary Figure S4: Effect of bicalutamide and OCT1002 on tumor growth in 22Rv1 xenografts Supplementary Figure S5: Stereological analysis of microvessels in LNCaP tumors grown in window chambers Supplementary Figure S6: Effect of bicalutamide on oxygenation of 22Rv1 xenografts